Loading...
•
Dec 31, 2024
Gilead Sciences Q4 2024 Earnings Report
Key Takeaways
Gilead Sciences reported strong Q4 2024 results with total revenue increasing by 6% year-over-year to $7.6 billion, driven by growth in HIV, Oncology, and Liver Disease product sales. EPS increased to $1.42 from $1.14 in Q4 2023, and non-GAAP EPS rose to $1.90. Operating income grew to $2.45 billion, supported by higher product sales and lower costs. Cash and cash equivalents stood at $10.0 billion as of December 31, 2024.
Gilead Sciences
Gilead Sciences
Gilead Sciences Revenue by Segment
Gilead Sciences Revenue by Geographic Location
Revenue by Segment
HIV Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comEurope Revenue
CapyFin.comRest of World Revenue
CapyFin.com Forward Guidance
Gilead expects stable revenue growth in 2025, with projected product sales between $28.2 billion and $28.6 billion. The company anticipates non-GAAP EPS in the range of $7.70 to $8.10, supported by strong HIV and Oncology demand.
Positive Outlook
- Continued strong demand for HIV and Oncology products
- Expansion in Liver Disease portfolio with new product launches
- Improved operational efficiencies driving margin growth
- Strong cash flow supporting dividend and stock repurchases
- Potential launch of lenacapavir for HIV PrEP in Summer 2025
Challenges Ahead
- Declining Veklury sales due to lower COVID-19 hospitalizations
- Higher operating expenses driven by litigation accruals and marketing costs
- Unrealized losses on equity investments impacting bottom line
- Increased R&D expenses due to new clinical trials and acquisitions
- Regulatory and pricing pressures in key markets